We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.
- Authors
Raaschou, P.; Simard, J. F.; Neovius, M.
- Abstract
An important clinical fear is that anti-tumor necrosis factor (anti-TNF) antibodies may accelerate tumor development. This fear is fuelled by its name, which in hindsight was a misnomer, and by case reports suggesting accelerated tumor development. The present carefully conducted study using nationwide registries indicates that the prognosis of cancer during anti-TNF treatment is identical to that without anti-TNF therapy. The important clinical message here is that effective anti-TNF treatment need not to be stopped when a patient develops cancer.
- Subjects
CANCER prognosis; TUMOR necrosis factors; RHEUMATOID arthritis; TUMOR growth; IMMUNOGLOBULINS; HEALTH outcome assessment; PATIENTS
- Publication
International Journal of Advances in Rheumatology, 2011, Vol 9, Issue 4, p143
- ISSN
1478-856X
- Publication type
Article